Table 3. Adjuvant and consolidation drug therapy in curative treatment algorithms.

Protocol	Median [95% CI; months]	Risk reduction (HR)	Reference
Cisplatin/vinorelbine vs. observation after surgery	Survival: 65.7 [47.9; 88.5] vs. 43.7 [35.7; 52.3]	0.8	(14)
Atezolizumab vs. observation after surgery and chemotherapy	Disease-free survival: n. a. [36.1; n.a.] vs. 35.3 [29.0; n. a.]	0.66	(15)
Osimertinib vs. placebo after surgery (and chemotherapy)	Disease-free survival: n. a. [38.8; n. a.] vs. 29.6 [16.6; 24.5]	0.17	(16)
Durvalumab vs. placebo (after radiotherapy)	Survival: n. a. [34.7; n. a.] vs. 28.7 [22.9; n. a.]	0.68	(19)

95% CI, 95% confidence interval; HR, hazard ratio; n. a., not attained at the time of publication; vs., versus